PERTINENT FINDINGS: Three types of IGRT (single dose, fractionated equidose, and fractionated low dose) were combined with low-dose TAT to determine the best combination of IGRT plus TAT in 2 CEA+ tumor models prior to selecting the best combination of IGRT plus TAT for inclusion with immunocytokine therapy. This evidence concerns the gene CEACAM5 and neoplasm.